135 related articles for article (PubMed ID: 19293512)
1. Halobetasol versus clobetasol: a study of potency.
Mohandas S; Rai R; Srinivas CR
Indian J Dermatol Venereol Leprol; 2009; 75(2):186-7. PubMed ID: 19293512
[No Abstract] [Full Text] [Related]
2. Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream.
Rigopoulos D; Ioannides D; Prastitis N; Katsambas A
Acta Derm Venereol; 2002; 82(2):140. PubMed ID: 12125946
[No Abstract] [Full Text] [Related]
3. Vitamin D and topical therapy.
Lebwohl M
Cutis; 2002 Nov; 70(5 Suppl):5-8. PubMed ID: 12467332
[TBL] [Abstract][Full Text] [Related]
4. Clobetasol--a potent new topical corticosteroid.
Med Lett Drugs Ther; 1986 Jun; 28(715):57-9. PubMed ID: 3520267
[No Abstract] [Full Text] [Related]
5. The role of clobetasol propionate emollient 0.05% in the treatment of patients with dry, scaly, corticosteroid-responsive dermatoses.
Gordon ML
Clin Ther; 1998; 20(1):26-39. PubMed ID: 9522102
[TBL] [Abstract][Full Text] [Related]
6. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo.
Coskun B; Saral Y; Turgut D
Eur J Dermatol; 2005; 15(2):88-91. PubMed ID: 15757818
[TBL] [Abstract][Full Text] [Related]
7. A novel halobetasol propionate 0.01%/tazarotene 0.045% fixed combination treatment for psoriasis.
Radonjic A; Evans EL
Dermatol Ther; 2019 Jul; 32(4):e12979. PubMed ID: 31155813
[No Abstract] [Full Text] [Related]
8. The efficacy of three class I topical synthetic corticosteroids, fluocinonide 0.1% cream, clobetasol 0.05% cream and halobetasol 0.05% cream: a Scholtz-Dumas bioassay comparison.
Lee CS; Koo J
J Drugs Dermatol; 2009 Aug; 8(8):751-5. PubMed ID: 19663113
[TBL] [Abstract][Full Text] [Related]
9. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement.
Lebwohl M; Yoles A; Lombardi K; Lou W
J Am Acad Dermatol; 1998 Sep; 39(3):447-50. PubMed ID: 9738781
[TBL] [Abstract][Full Text] [Related]
10. The treatment of vulval lichen sclerosus with a very potent topical steroid (clobetasol propionate 0.05%) cream.
Dalziel KL; Millard PR; Wojnarowska F
Br J Dermatol; 1991 May; 124(5):461-4. PubMed ID: 2039723
[TBL] [Abstract][Full Text] [Related]
11. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis.
Lebwohl M; Siskin SB; Epinette W; Breneman D; Funicella T; Kalb R; Moore J
J Am Acad Dermatol; 1996 Aug; 35(2 Pt 1):268-9. PubMed ID: 8708035
[No Abstract] [Full Text] [Related]
12. Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis.
Lebwohl MG; Sugarman JL; Gold LS; Pariser DM; Lin T; Pillai R; Martin G; Harris S; Israel R
J Am Acad Dermatol; 2019 Jan; 80(1):282-285. PubMed ID: 30227193
[No Abstract] [Full Text] [Related]
13. Dermatopharmacologic investigations of halobetasol propionate in comparison with clobetasol 17-propionate.
Yawalkar S; Wiesenberg-Boettcher I; Gibson JR; Siskin SB; Pignat W
J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1137-44. PubMed ID: 1757603
[TBL] [Abstract][Full Text] [Related]
14. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in the treatment of plaque psoriasis.
Kerdel FA; Draelos ZD; Tyring SK; Lin T; Pillai R
J Dermatolog Treat; 2019 Jun; 30(4):333-339. PubMed ID: 30207807
[No Abstract] [Full Text] [Related]
15. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
[TBL] [Abstract][Full Text] [Related]
16. Calcipotriol ointment versus clobetasol ointment in localized vitiligo: an open, comparative clinical trial.
Köse O; Riza Gür A; Kurumlu Z; Erol E
Int J Dermatol; 2002 Sep; 41(9):616-8. PubMed ID: 12358838
[No Abstract] [Full Text] [Related]
17. An investigator-initiated, double-blind, vehicle-controlled pilot study: assessment for tachyphylaxis to topically occluded halobetasol 0.05% ointment in the treatment of psoriasis.
Czarnowicki T; Linkner RV; Suárez-Fariñas M; Ingber A; Lebwohl M
J Am Acad Dermatol; 2014 Nov; 71(5):954-959.e1. PubMed ID: 24929883
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of halobetasol propionate lotion 0.01% in the treatment of moderate to severe plaque psoriasis: a pooled analysis of 2 phase 3 studies.
Sugarman JL; Weiss JS; Tanghetti EA; Soung J; Yamauchi PS; Lin T; Harris S; Martin G; Pillai R
Cutis; 2019 Feb; 103(2):111-116. PubMed ID: 30893392
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials.
Green LJ; Kerdel FA; Cook-Bolden FE; Bagel J; Lin T; Martin G; Pillai R; Israel R; Ramakrishna T
J Drugs Dermatol; 2018 Oct; 17(10):1062-1069. PubMed ID: 30365586
[TBL] [Abstract][Full Text] [Related]
20. Comparison of clinical efficacy of topical tazarotene 0.1% cream with topical clobetasol propionate 0.05% cream in chronic plaque psoriasis: a double-blind, randomized, right-left comparison study.
Angelo JS; Kar BR; Thomas J
Indian J Dermatol Venereol Leprol; 2007; 73(1):65. PubMed ID: 17319037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
